SGN 17/19
Alternative Names: SGN-17/19Latest Information Update: 18 Dec 2023
At a glance
- Originator Seattle Genetics
- Developer Genencor International; Seattle Genetics
- Class Antineoplastics; Immunoglobulin fusion proteins; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Malignant melanoma